The recent survival benefit of adjuvant chemotherapy in early stage non-small cell lung cancer provides optimism for the future success of targeted therapy in this setting. It is important that we begin to explore molecularly targeted agents in the adjuvant arena, but how best to accomplish this in the face of these new findings presents a challenge. Criteria for selecting promising targeted therapies and optimal trial designs to evaluate them expeditiously in the adjuvant setting are clearly needed.
|Original language||English (US)|
|Journal||Clinical cancer research : an official journal of the American Association for Cancer Research|
|Issue number||13 Pt 2|
|State||Published - Jul 1 2005|
ASJC Scopus subject areas
- Cancer Research